Vertex Pharmaceuticals. has been granted a patent for immunomodulatory proteins featuring variant PD-1 polypeptides. These proteins, which include specific amino acid substitutions, are designed for therapeutic applications in various immunological and oncological conditions, along with methods for their production and use. GlobalData’s report on Vertex Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vertex Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Vertex Pharmaceuticals's grant share as of July 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
Immunomodulatory proteins with variant pd-1 polypeptides
The granted patent US12065476B2 presents a novel variant PD-1 polypeptide characterized by specific amino acid substitutions within an unmodified PD-1 polypeptide. The claims detail a comprehensive list of substitutions that can enhance the polypeptide's properties, particularly its binding affinity to the ectodomain of human PD-L1. The patent outlines that the variant PD-1 polypeptide can include one or more substitutions from a specified list, or two or more substitutions from a different subset, with reference to the amino acid positions defined in SEQ ID NO:37. Additionally, the polypeptide may comprise an IgV domain, which is crucial for its immunological functions.
The patent further expands on the applications of the variant PD-1 polypeptide, including its incorporation into immunomodulatory proteins linked to multimerization domains, such as Fc domains with reduced effector function. It also covers conjugates that link the variant PD-1 polypeptide to targeting moieties for specific cell surface interactions. Furthermore, the claims encompass engineered cells, infectious agents, and pharmaceutical compositions that utilize the variant PD-1 polypeptide, thereby highlighting its potential therapeutic applications in modulating immune responses. The patent also includes provisions for articles of manufacture containing the pharmaceutical compositions, indicating a pathway for commercialization.
To know more about GlobalData’s detailed insights on Vertex Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
